antipyrine has been researched along with Fatty Liver in 11 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Medroxyprogesterone acetate (MPA) elimination rate was investigated in 25 patients with primary biliary cirrhosis, alcoholic cirrhosis and fatty liver." | 3.67 | Liver function and medroxyprogesterone acetate elimination in man. ( Rautio, A, 1984) |
| " Studies were undertaken using an in situ-perfused rat liver and multiple indicator dilution, and outflow data were analyzed with a physiologically based organ pharmacokinetic model." | 1.37 | Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Thorling, CA; Zhang, Q, 2011) |
| " Thus, the drug-metabolizing capacity in diabetics seems to be markedly reduced, and drug dosage might have to take account of this fact." | 1.27 | [Antipyrine clearance as a measure of drug metabolism in patients with diabetes mellitus]. ( Dennin, DE; Oltmanns, D; Pentz, R; Siegers, CP, 1984) |
| "The antipyrine test was selected as an in vivo index, since its kinetics indirectly reflect the metabolically active liver mass." | 1.26 | The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus. ( Pelkonen, RO; Salmela, PI; Sotaniemi, EA, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (90.91) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, P | 1 |
| Robertson, TA | 1 |
| Thorling, CA | 1 |
| Zhang, Q | 1 |
| Fletcher, LM | 1 |
| Crawford, DH | 1 |
| Roberts, MS | 1 |
| Rautio, A | 1 |
| Oltmanns, D | 1 |
| Dennin, DE | 1 |
| Pentz, R | 1 |
| Siegers, CP | 1 |
| Pirttiaho, HI | 1 |
| Salmela, PI | 2 |
| Sotaniemi, EA | 3 |
| Pelkonen, RO | 3 |
| Pitkänen, U | 1 |
| Luoma, PV | 2 |
| Arranto, A | 1 |
| Ehnholm, C | 1 |
| Ohnhaus, EE | 1 |
| Münch, U | 1 |
| Meier, J | 1 |
| Hartleb, M | 1 |
| Markiewicz, A | 1 |
| Rudzki, K | 1 |
| Nowak, S | 1 |
| Bołdys, H | 1 |
| Kacperek, T | 1 |
| Altmann, HW | 1 |
| Ackermann, E | 1 |
| Renger, F | 1 |
| Dökert, B | 1 |
| Walther, M | 1 |
| Kanetaka, T | 1 |
| Oda, T | 1 |
11 other studies available for antipyrine and Fatty Liver
| Article | Year |
|---|---|
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cations; Cytochrome P-450 | 2011 |
Liver function and medroxyprogesterone acetate elimination in man.
Topics: Antipyrine; Fatty Liver; Female; Humans; Liver; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary | 1984 |
[Antipyrine clearance as a measure of drug metabolism in patients with diabetes mellitus].
Topics: Adolescent; Adult; Aged; Antipyrine; Diabetes Mellitus, Type 1; Fatty Liver; Humans; Liver Cirrhosis | 1984 |
Drug metabolism in diabetic subjects with fatty livers.
Topics: Adult; Aged; Antipyrine; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Fatty Liver; Fem | 1984 |
Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver.
Topics: Adult; Aged; Antipyrine; Apoproteins; Biopsy; Cholesterol; Cholesterol, HDL; Cytochrome P-450 Enzyme | 1982 |
The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus.
Topics: Antipyrine; Cytochrome P-450 Enzyme System; Diabetes Complications; Diabetes Mellitus; Fatty Liver; | 1980 |
[Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
Topics: Antipyrine; Fatty Liver; Hepatitis; Humans; Liver Cirrhosis; Liver Diseases; Pindolol | 1976 |
[Diurnal variability of hepatic clearance of antipyrine and Tc-99m-HIDA in healthy persons and in those with liver diseases. I].
Topics: Adult; Aged; Antipyrine; Circadian Rhythm; Contrast Media; Fatty Liver; Humans; Imino Acids; Liver; | 1987 |
Morphological changes in the liver due to phenazone and its derivatives.
Topics: Antipyrine; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Fatty Liver; Granulom | 1986 |
[Aminophenazone half life in patients with chronic liver parenchyma disorders].
Topics: Aminopyrine; Animals; Antipyrine; Chronic Disease; Fatty Liver; Female; Half-Life; Hepatitis; Humans | 1972 |
Toxic liver injuries.
Topics: Anti-Bacterial Agents; Antipyrine; Antitubercular Agents; Biopsy; Carbon Tetrachloride Poisoning; Ce | 1973 |